EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2565-2571

  Alaminos, Miguel ^a,b   Dávalos, Verónica ^a   Ropero, Santiago ^a   Setién, Fernando ^a   Paz, Maria F ^a   Herranz, Michel ^a   Fraga, Mario F ^a   Mora, Jaume ^c   Cheung, Nai Kong V ^d   Gerald, William L ^d   Esteller, Manel ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; EPITHELIAL MEMBRANE PROTEIN 3; MYELIN ASSOCIATED GLYCOPROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL INTERACTION; CELL PROLIFERATION; CHROMOSOME 19Q; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DENSITY; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; FEMALE; GANGLIONEUROMA; GENE EXPRESSION PROFILING; GENE LOCATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; METHYLATION; MOLECULAR PROBE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 19; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; FEMALE; GANGLIONEUROMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; MEDULLOBLASTOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; NEOPLASM STAGING; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 20144387913     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4283     Document Type: Article

References (40)

1. Castleberry RP. Neuroblastoma. Eur J Cancer 1997;33:1430-7.
2. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003;4:472-80.
3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
4. Ueki K, Ramaswamy S, Billings SJ, Mohrenweiser HW, Louis DN. ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3. Neurogenetics 1997;1:31-6.
5. Brodeur GM, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott; 2002. p. 895-937.
6. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
7. Alaminos M, Davalos V, Cheung NK, Gerald WL, Esteller M. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst 2004;96:1208-19.
8. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
9. Mora J, Cheung NK, Chen L, Qin J, Gerald W. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res 2001;7:1358-61.
10. Levin VA, Gutin PH, Leibel S. Neoplasms of the central nervous system. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. Philadelphia: Lippincott; 1993. p. 1679-737.
11. Bello MJ, Leone PE, Vaquero J, et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 1995;64:207-10.
12. Fallon KB, Palmer CA, Roth KA, et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004;63:314-22.
13. Maintz D, Fiedler K, Koopmann J, et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997;56:1098-104.
14. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch 1995;427:113-8.
15. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-52.
16. Smith JS, Tachibana I, Lee HK, et al. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000;29:16-25.
17. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
18. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000;60:129-33.
19. Taylor V, Suter U. Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family. Gene 1996;175:115-20.
20. Ben-Porath I, Benvenisty N. Characterization of a tumor-associated gene, a member of a novel family of genes encoding membrane glycoproteins. Gene 1996;183:69-75.
21. Liehr T, Kuhlenbaumer G, Wulf P, et al. Regional localization of the human epithelial membrane protein genes 1, 2, and 3 (EMP1, EMP2, EMP3) to 12p12.3, 16p13.2, and 19q13.3. Genomics 1999;58:106-8.
22. Mora J, Cheung NK, Kushner BH, et al. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn 2000;2:37-46.
23. Mora J, Gerald WL, Cheung NK. Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett 2003;197:119-24.
24. Alaminos M, Mora J, Cheung NK, et al. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Res 2003;63:4538-46.
25. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
26. Schwab M. MYCN in neuronal tumours. Cancer Lett 2004;204:179-87.
27. Hartmann C, Johnk L, Kitange G, et al. Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res 2002;62:4100-8.
28. Rubio MP, Correa KM, Ueki K, et al. The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. Cancer Res 1994;54:4760-3.
29. Rosenberg JE, Lisle DK, Burwick JA, et al. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996;13:2483-5.
30. Jetten AM, Suter U. The peripheral myelin protein 22 and epithelial membrane protein family. Prog Nucleic Acid Res Mol Biol 2000;64:97-129.
31. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
32. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002;21:5427-40.
33. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
34. Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-8.
35. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
36. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
37. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
38. Costello JF, Berger MS, Huang HS, Cavenee WK. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 1996;56:2405-10.
39. van Noesel MM, van Bezouw S, Salomons GS, et al. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DCR1 and DCR2 is associated with dense promoter hypermethylation. Cancer Res 2002;62:2157-61.
40. Hong C, Bollen AW, Costello JF. The contribution of genetic and epigenetic mechanisms to gene silencing in oligodendrogliomas. Cancer Res 2003;63:7600-5.